Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.7%

5 terminated/withdrawn out of 22 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

12%

2 of 17 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
12(54.5%)
Phase 1
8(36.4%)
Early Phase 1
1(4.5%)
Phase 3
1(4.5%)
22Total
Phase 2(12)
Phase 1(8)
Early Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT03139916Phase 2Completed

Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Role: collaborator

NCT01323062Phase 1Completed

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Role: collaborator

NCT01335204Phase 1Terminated

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Role: collaborator

NCT02651610Phase 2Withdrawn

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Role: lead

NCT01632696Early Phase 1Terminated

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

Role: lead

NCT01999673Phase 3Completed

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

Role: lead

NCT00669591Phase 2Completed

A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Role: lead

NCT01138163Phase 2Completed

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Role: lead

NCT01272791Phase 2Completed

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Role: lead

NCT01160601Phase 2Completed

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Role: lead

NCT02685306Phase 2Withdrawn

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Role: lead

NCT02673814Phase 2Withdrawn

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Role: lead

NCT00677716Phase 2Completed

Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

Role: lead

NCT01273948Phase 1Completed

Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

Role: lead

NCT00509301Phase 1Completed

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

Role: lead

NCT00503347Phase 1Completed

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

Role: lead

NCT00687817Phase 2Completed

Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Role: lead

NCT00669565Phase 2Completed

Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer

Role: lead

NCT00129337Phase 1Completed

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

Role: lead

NCT00004017Phase 2Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

Role: lead